Humacyte (NASDAQ:HUMA) Given New $10.00 Price Target at Benchmark

Key Points

• Benchmark lowered its price target on Humacyte from $11.00 to $10.00 while maintaining a "buy" rating; overall analyst coverage shows seven Buys and one Sell with a consensus price target of $8.14 and an average rating of "Moderate Buy".
• Shares traded around $1.04 (market cap ~$193.8M) with negative earnings (PE -4.5) and analysts forecasting about -$1.27 EPS for the current fiscal year, highlighting the stock's low market valuation versus analyst targets.
• Humacyte is a clinical-stage biotech developing off-the-shelf regenerative human acellular vessels (HAVs) for vascular access and repair, with its lead HAV showing promising trial results for durability and reduced infection rates.

Humacyte (NASDAQ:HUMA - Get Free Report) had its target price decreased by investment analysts at Benchmark from $11.00 to $10.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock.

A number of other research firms have also weighed in on HUMA. BTIG Research restated a "buy" rating and set a $6.00 target price on shares of Humacyte in a research note on Friday, November 21st. Weiss Ratings restated a "sell (d-)" rating on shares of Humacyte in a research note on Monday, December 29th. UBS Group restated a "buy" rating on shares of Humacyte in a research report on Monday, December 1st. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday, December 21st. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research note on Monday, January 5th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $8.14.

Humacyte Trading Up 1.5%

Shares of HUMA stock traded up $0.02 during trading hours on Wednesday, hitting $1.04. The company had a trading volume of 1,733,105 shares, compared to its average volume of 4,547,753. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. The stock has a market capitalization of $193.82 million, a PE ratio of -4.50 and a beta of 1.93. The company's fifty day moving average is $1.17 and its 200 day moving average is $1.61. Humacyte has a fifty-two week low of $0.91 and a fifty-two week high of $4.85.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. The company had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.92 million. Research analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humacyte

Large investors have recently modified their holdings of the stock. Lazari Capital Management Inc. acquired a new position in Humacyte during the 2nd quarter worth approximately $27,000. Prudential Financial Inc. purchased a new stake in shares of Humacyte during the second quarter valued at approximately $28,000. Financial Advisors Network Inc. acquired a new position in shares of Humacyte during the second quarter worth $28,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Humacyte in the second quarter valued at $30,000. Finally, Valeo Financial Advisors LLC purchased a new position in shares of Humacyte in the second quarter valued at $32,000. Institutional investors and hedge funds own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.